Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5754062 | 0.99 | MEN1 (0.55) | MEN1CYP2C9KMT2APPARGPPARA | |
| SCHEMBL5757702 | 0.92 | MEN1 (0.66) | MEN1CYP2C9KMT2APPARGPPARA | |
| SCHEMBL5757648 | 0.91 | MEN1 (0.67) | MEN1CYP2C9KMT2APPARGPPARA | |
| SCHEMBL5755818 | 0.91 | PPARG (0.46) | MEN1CYP2C9KMT2APPARGPPARA | |
| SCHEMBL5756783 | 0.90 | MEN1 (0.45) | MEN1CYP2C9KMT2APPARGPPARA | |
| SCHEMBL5753295 | 0.90 | PPARA (0.45) | MEN1CYP2C9KMT2APPARGPPARA | |
| SCHEMBL5756877 | 0.89 | MEN1 (0.45) | MEN1CYP2C9KMT2APPARGPPARA | |
| SCHEMBL5759745 | 0.89 | ALDH1A1 (0.50) | PPARGPPARAPPARDALDH1A1GAA | |
| SCHEMBL5754076 | 0.89 | ALDH1A1 (0.50) | PPARGPPARAPPARDALDH1A1GAA | |
| SCHEMBL5759104 | 0.89 | ALDH1A1 (0.50) | PPARGPPARAPPARDALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1208092-B1 | SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR | SAMSUNG ELECTRONICS CO LTD (KR) | 2006-06-21 | — | — | EP | disclosed |
| US-6548667-B2 | For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase | SAMSUNG ELECTRONICS CO. LTD. (KR) | 2003-04-15 | — | — | US | disclosed |
| US-20020169314-A1 | Sulfonamide derivative as a matrix metalloproteinase inhibitor | SAMSUNG ELECTRONICS CO. LTD. (KR) | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169314-A1 | Sulfonamide derivative as a matrix metalloproteinase inhibitor | MMP9, MMP3, MMP14 | MEN1 2541/4885CYP2C9 874/4885KMT2A 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.